Skip to main content
Full access
Regular Articles
Published Online: 27 February 2020

Alcohol Use, Mental Health, and Functional Capacity as Predictors of Workplace Disability in a Cohort With Manifest Huntington’s Disease

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences

Abstract

Objective:

Huntington’s disease (HD) is an inherited neurodegenerative disease involving motor, cognitive, psychiatric, and behavioral impairments that eventually affect work-role functioning. There is limited research regarding predictors of workplace disability in HD. The authors examined predictors of work impairment and disability in a cross-sectional cohort of employed persons with symptomatic HD participating in the worldwide Enroll-HD study.

Methods:

The study sample (N=316) comprised individuals with manifest HD and a CAG repeat length range between 39 and 60 and were currently engaged in paid full- or part-time employment. Univariate and multivariate logistic regression analyses identified predictors and the effect of all predictors in a fully adjusted model.

Results:

Of the sample, 20.3% reported missing work due to HD, 60.1% reported experiencing impairment while working due to HD, 79.1% reported having work-related activity impairment due to HD, and 60.8% reported impairment in overall work productivity due to HD. Individuals had 25% higher odds of missing work time if they had a higher level of functional impairment (odds ratio=0.76, 95% CI=0.64, 0.91) and had three times greater odds of missing work if they were current alcohol drinkers, compared with nondrinkers (odds ratio=2.86, 95% CI=1.62, 5.03). Individuals with lower self-perceived mental health were also 5% more likely to experience impairment at work due to HD. Motor impairment was not a strong predictor of workplace disability.

Conclusions:

These findings provide important new knowledge that can inform the development of strategies or targeted intervention trials to support persons with symptomatic HD to maintain their work roles.
Employment is important for financial security, social activity, personal satisfaction, and achievement (1). In contrast, extended work disability is associated with negative outcomes, including financial hardship, loss of self-esteem, social isolation, and increased mental health problems (2). Work disability is also associated with increased costs, such as health service use, sick leave, and indirect costs due to the loss of work productivity, wage replacement, retirement, and disability pensions. Overall, there is agreement that employment is beneficial for people economically and has physical and mental well-being benefits—and this is no different for people with cognitive impairment or dementia (3). Systematic reviews have reported health benefits for individuals with dementia or mild cognitive impairment who continue to engage in meaningful occupation (4). Moreover, psychologically complex and challenging work may have a preventive effect, reducing the impact or delaying the cognitive and functional decline associated with dementia (5).
The ability of individuals with neurodegenerative disorders to meet job expectations is a concern of employers, employees and their families, and clinicians and is a global public health, economic, and social issue. This is particularly so for those under age 65 who are diagnosed as having younger-onset dementia. In addition to financial consequences, changes in sense of identity; decreased self-worth, social contact, and meaningful occupation (610); and performance problems, coupled with potential personality changes, may result in difficult or traumatic transitions from employment (11). Loss of the work role often increases stress for the family, because of financial strain and increased working hours and stress for other family members. Additional stress can occur when the person with younger-onset cognitive impairment or dementia feels “out of place” as these transitions occur “out of time” in a “usual” life cycle, with symptoms occurring in midlife in contrast to the more well-known neurodegenerative disorders that become symptomatic later in life (such as late-onset Alzheimer’s disease).
Huntington’s disease (HD) is a neurodegenerative disease that often results in a younger-onset dementia. It is caused by mutations in the Huntingtin (HTT) gene, which involves an expanded and unstable DNA segment known as a CAG trinucleotide repeat (12). Symptoms include progressively worsening motor, cognitive, and psychiatric-behavioral symptoms. The onset of these symptoms and subsequent formal clinical diagnosis typically occur during the fourth or fifth decade of life, the age range when many individuals are at the peak of their careers and earning potential and when they often have significant financial commitments. The symptoms of HD have a strong impact on function and quality of life and affect a person’s ability to maintain daily functions, including work functions and occupational status, and eventually result in reduced work hours or cessation of work (13, 14). Indeed, difficulties maintaining employment have been reported as having the greatest impact on daily life for people with HD and their families (15).
Overall, there is a paucity of research on the factors associated with work disability in dementia; therefore, knowledge on how best to support individuals with their employment after diagnosis is limited (16) and is even more limited in cases of younger-onset dementias such as HD. One study of 220 employed and unemployed Enroll-HD participants at the Leiden University Medical Center, with and without a clinical motor diagnosis, found that HD mutation carriers with poorer cognitive performance and higher apathy scores were more likely to be unemployed, compared with HD mutation carriers with higher cognitive scores and no signs of apathy. Cognitive impairments, especially in the executive domain, and apathy were independent determinants of unemployment in HD mutation carriers. Motor disturbances, the clinical hallmark of HD, did not appear to be the most important predictor for work cessation (17).
We have previously examined factors related to workplace disability in individuals with premanifest HD and found that higher numbers of CAG repeats and more motor symptoms were associated with significantly higher odds of experiencing workplace impairment (18). In addition, several modifiable factors, including physical and mental health, were found to be related to workplace disability in people with premanifest HD. Building on this work, we aimed in the study reported here to identify significant factors associated with work impairment and disability in a cohort of employed, symptomatic individuals with HD. The focus of this study was thus on the following question: What are the predictors of workplace disability outcomes in people with manifest HD? We hypothesized that higher numbers of CAG repeats, more motor symptoms, greater cognitive impairment, and greater physical and mental health impairments would be associated with higher odds of experiencing workplace impairment.

Methods

Participants

Enroll-HD (ClinicalTrials.gov identifier NCT01574053) is a global clinical research platform designed to facilitate clinical research in HD. As of July 1, 2019, there were 18,845 active participants enrolled at 174 sites in 19 countries. Individuals with premanifest HD or manifest HD, genotype negative or unknown, family members, and community controls participate in the Enroll-HD study. The diagnosis of HD is based on two factors: investigator-determined status, including clinical signs and symptoms, and genotyping status. Participants are classified as manifest HD if they show evidence of clinically significant motor symptoms (diagnostic confidence level of 4 from the Unified Huntington’s Disease Rating Scale [UHDRS], which is associated with motor abnormalities that are considered unequivocal signs of HD, scored by the investigator).
All enrolled participants undergo an annual assessment using a core data set covering motor, cognitive, and behavioral symptoms, with assessments also exploring work productivity measures, quality of life, and physical functioning. All sites are required to obtain and maintain local Ethics Committee approvals, and the project conforms to the provisions of the Declaration of Helsinki. Written informed consent was obtained from all participants. Data are monitored for quality and accuracy by using a risk-based monitoring approach, and all participants are deidentified.
For this study, we analyzed the third Enroll-HD baseline data set, extracted from the database on October 31, 2016, and made available on December 15, 2016. The sample consisted of 316 participants who were classified as manifest HD, having a CAG repeat length range between 39 and 60, and currently engaged in paid full- or part-time employment, who provided data (at least one subscale total) about work disability outcomes as measured by the Work Productivity and Activity Impairment-Specific Health Problem (WPAI-SHP) questionnaire.

Assessments and Measures

Data were collected on the following measures from included participants.

Sociodemographic and lifestyle factors.

Data were collected on age, gender, region, marital status, smoking and alcohol consumption status, employment status, and years of education.

Clinical and neuropsychological measures.

Motor symptoms were assessed with the UHDRS Total Motor Scale (TMS) (19). The TMS score reflects the sum of ratings on 31 items in 15 domains of motor impairment, each rated on a 5-point scale, ranging from 0, normal, to 4, severest impairment. The motor items rate oculomotor functioning (six items), chorea (seven items), dystonia (five items), bradykinesia (11 items), and rigidity (two items). The maximum possible total score is 124. Functional assessment was conducted by using the UHDRS Total Functional Capacity (TFC) scale (19). Global cognitive functioning was examined with the Mini-Mental State Examination (MMSE) (20). Anxiety, depressive, and irritability symptoms were assessed with the Hospital Anxiety and Depression Scale (HADS) (21) and Snaith Irritability Scale (22). Overall physical and mental health was measured by using the 12-item Short-Form Health Survey (SF-12) (23). CAG repeat length was determined with laboratory genotyping.

Work productivity measure.

The impact of HD on work productivity was examined with the WPAI-SHP questionnaire (24), a self-report instrument used to assess work productivity loss due to general health or a specified health problem. The WPAI-SHP consists of four subscales, the total scores for which are calculated as impairment percentages (from 0% to 100%), with higher numbers indicating greater impairment and less productivity (i.e., worse outcomes). The first subscale, absenteeism (work time missed due to illness or disease), includes any time taken off from work due to HD. The second subscale, presenteeism, is the reported percentage of impairment while at work due to illness or disease. The third subscale, activity impairment, is a global assessment of any work-related activity impairment due to illness or disease. The fourth subscale, work productivity loss–overall work impairment, refers to the participant’s overall productivity (on average) on days at work. The WPAI-SHP is a robust measure of work productivity, which has been validated as a measure of work-related impairment for numerous diseases (e.g., 25, 26).

Statistical Analysis

Because cell sizes were small for certain categories of predictor variables, some of the predictor variable categories were combined prior to analysis. Region was combined into three categories: Australasia, Europe, and the Americas (North and Latin America). Years of education was combined into three categories: below diploma (International Standard Classification of Education [ISCED] levels 0, 1, 2, and 3), diploma-certificate (ISCED level 4), and tertiary studies (ISCED levels 5 and 6). Dichotomized variables were marital status (single versus married or in a partnership); residence (town or city versus rural or village), and smoking and drinking status (alcohol drinker versus nondrinker, smoker versus nonsmoker). Employment status was categorized as full-time, part-time, and self-employed. To address study aims (and because the WPAI-SHP data for our sample were zero inflated), the WPAI-SHP variables were dichotomized into presence or absence of any impairment for analysis by using binary logistic regression models, following the approach suggested in the literature (27).
In the data set, values were missing for 11 of the 22 variables, with the proportions ranging from 0.3% (residence and TMS) to 32.6% (overall work impairment). Of the 316 individuals who constituted the study cohort, 46.5% had one or more missing values, with the missing values in total accounting for 5.2% of the total values. Before the transformation of the four WPAI-SHP variables mentioned above and formal data analysis, we performed multiple imputation to address the missing data based on the assumption that data were missing at random (2830). Specifically, we included all baseline variables of interest in the imputation model, selected “Automatic” imputation method, set the number of imputations as 35 (slightly larger than the highest proportion of missing values [32.6%] for the variable overall work impairment), and set constraints for all continuous variables to ensure that the imputed values would be within the normal range of the variables (29, 31). After creating 35 imputed data sets, we used standard statistical methods (logistical regression) to fit the model of interest to each of the imputed data sets. Estimated associations in each imputed data set were averaged together to give overall estimated associations between the predictor variables and outcome variables (28, 29).
We calculated mean values and SDs as well as frequencies and percentages for sociodemographic, lifestyle, clinical, and neuropsychological measures. To identify significant predictors of the four WPAI-SHP outcomes, we first conducted a series of univariate logistic regression analyses (“Enter” method) for each outcome variable using the imputed data sets. Variables with a p value <0.25 were included in a multivariable logistic regression analysis (“Enter” method) for each WPAI-SHP outcome (32). We also conducted the same regression analyses using the data set with missing data and found some different significant factors. Given that missing data, if not specified, can lead to the loss of power and potentially biased results, we reported the results of the imputed data sets (31).
Collinearity of all predictor variables were tested by using the linear regression procedure. Statistical significance was assessed using a p value <0.05 and a 95% confidence interval in logistic regression models. Odds ratios were used to quantify the association between independent and outcome variables. All analyses were performed using SPSS 22 (IBM Corporation, Armonk, N.Y.).

Results

Demographic Characteristics

Sociodemographic, lifestyle, clinical, and neuropsychological characteristics are summarized in Table 1. Most participants were male (52.5%), were married or in a partnership (61.7%), worked full-time (64.2%), and lived in a town or city (79.7%). The mean age of participants was 47.0 years (SD=10.5, range 22–76), and most were from Europe (64.2%), followed by the Americas (30.7%) and Australasia (5.1%).
TABLE 1. Demographic and clinical characteristics of persons with manifest Huntington’s disease (N=316)a
CharacteristicN with dataN%MeanSDRange
Sociodemographic and lifestyle      
 Age (years)   47.010.522–76
 Female gender31615047.5   
 Residence315     
  Town or city 25179.7   
  Rural or village 6420.3   
 Education level316     
  Below high school diploma 16050.6   
  High school diploma or leaving certificate 5517.4   
  Tertiary study 10132.0   
 Region316     
  The Americas 9730.7   
  Europe 20364.2   
  Australasia 165.1   
 Marital status316     
  Single, unmarried 12138.3   
  Married or in a partnership 19561.7   
 Employment status316     
  Full-time 20364.2   
  Part-time 8426.6   
  Self-employed 299.2   
 Current drinker31615047.5   
 Current smoker3169530.1   
Clinical and neuropsychological      
 MMSE score282  27.22.420–30
 TMS score315  24.412.90–87
 TFC scale score   11.51.74–13
 HADS-A subscale score298  6.84.20–21
 HADS-D subscale score298  6.04.00–18
 Snaith Irritability Scale score297  6.64.50–20
 SF-12 PCS303  50.78.617.4–66.8
 SF-12 MCS303  44.210.816.5–62.2
 CAG repeat length   44.53.439–60
 WPAI-SHP      
  Absenteeism (missed work time)2826420.3   
  Presenteeism (impairment while working)21419060.1   
  Activity impairment31225079.1   
  Overall work impairment21319260.8   
a
HADS-A=Hospital Anxiety and Depression Scale anxiety subscale, HADS-D=Hospital Anxiety and Depression Scale depression subscale, MMSE=Mini-Mental State Examination, SF-12 MCS=12-item Short-Form Health Survey mental component score, SF-12 PCS=12-item Short-Form Health Survey physical component score, TFC=Total Functional Capacity scale of the Unified Huntington’s Disease Rating Scale, TMS=Total Motor Scale, WPAI-SHP=Work Productivity and Activity Impairment-Specific Health Problem.
Mean CAG repeat length was 44.5 (SD=3.4, range=39–60). Participants had a mean TMS score of 24.4 (SD=12.9, range=0–87), which suggested a wide variability in motor symptoms in the participants classified as manifest HD (the maximum possible total TMS score is 124). Nevertheless, all included participants had been classified clinically as having manifest HD by the Enroll-HD study investigators on the basis of the criteria described above. Higher scores on the TMS indicate more impaired motor function, and individuals with manifest HD are classified in Enroll-HD based on TMS scores >5 (as consistent with previous literature [33]). In our sample, 308 participants had a TMS score >5 (97.7% of our cohort).
Participants had a mean MMSE score of 27.2 out of a possible 30 (SD=2.4, range=20–30), indicating minimal cognitive impairment. The mean TFC score was close to the maximum level of functioning of 13 (11.5, SD=1.7, range=4–13). The mean total scores on both the HADS anxiety (HADS-A) and HADS depression (HADS-D) subscales were below the cutoff score of 7, indicating absence of clinically relevant symptoms of anxiety and depression (HADS-A: 6.8, SD=4.2, range=0–21; HADS-D: 6.0, SD=4.0, range=0–18). Likewise, participants fell significantly below the cutoff score of 14 points for irritability measured by the Snaith Irritability scale (6.6, SD=4.5, range=0–20). On the SF-12, the mean physical composite score (PCS) (50.7, SD=8.6) and the mean mental composite score (MCS) (44.2, SD=10.8) indicated an “average” level of physical and mental health in this sample, according to the normative mean of 50.

Workplace Impairment and Associated Significant Factors

As shown in Table 1, the proportion of participants who reported having missed work due to HD symptoms was 20.3% (N=64). The proportion who reported experiencing impairment while working due to HD was 60.1% (N=190). In addition, 79.1% (N=250) reported having work-related activity impairment due to HD, and 60.8% (N=192) reported experiencing impairment in overall work productivity due to HD.
Based on the results of univariate logistic regression analyses using the significance level of 0.25, the potential significant predictors for each outcome were determined. For absenteeism, they were education (p=0.15), current alcohol use (p<0.001), TMS score (p=0.08), SF-12 MCS (p=0.01), TFC score (p<0.001), MMSE score (p=0.03), HADS-D score (p=0.01), irritability score (p=0.02), and SF-12 PCS (p=0.01). For presenteeism, they were region (p<0.01), current alcohol use (p=0.06), current smoker (p=0.06), TFC score (p=0.02), HADS-D score (p=0.11), irritability score (p=0.08), and SF-12 MCS (p=0.01). For activity impairment, they were current alcohol use (p=0.20), current smoker (p=0.15), TMS score (p=0.08), TFC score (p=0.06), HADS-A score (p<0.001), HADS-D score (p<0.001), irritability score (p<0.001), SF-12 PCS (p=0.026), and SF-12 MCS (p<0.001). For overall work impairment, they were region (p=0.12), current alcohol use (p=0.18), current smoker (p=0.12), TFC score (p=0.04), HADS-A score (p=0.24), irritability score (p=0.09), and SF-12 MCS (p=0.02),
On the basis of multivariable logistic regression analyses of the imputed data sets, we identified significant (p<0.05) factors associated with two outcomes (Table 2). For absenteeism, significant factors included current alcohol use (odds ratio=2.86, 95% CI=1.62, 5.03) and TFC score (odds ratio=0.76, 95% CI=0.64, 0.91). Significant factors for activity impairment included SF-12 MCS (odds ratio=0.95, 95% CI=0.897, 0.995). In contrast, no significant factors were identified for the other two outcomes—presenteeism and work productivity loss–overall work impairment.
TABLE 2. Variables significantly associated with work disability due to Huntington’s disease (HD) reported by a cohort of persons with manifest HDa
 Imputed data analysis (N=316)Complete-case analysis (N=169)
Disability area and variablebOdds ratioSEp95% CIOdds ratioSEp95% CI
Absenteeism        
 Alcohol use2.860.29<0.0011.62, 5.033.610.420.0021.60, 8.14
 TFC scale scorec0.760.090.0020.64, 0.910.780.120.0410.62, 0.99
 SF-12 PCSd    0.960.020.0500.92, 1.00
Presenteeism        
 TFC scale scorec    0.420.340.0100.22, 0.81
Activity impairment        
 SF-12 MCSe0.950.030.030.897, 0.9950.930.030.0210.87, 0.99
 Gender    2.370.440.0471.01, 5.57
Overall impairment        
 TFC scale scorec    0.380.370.0090.18, 0.78
a
Logistic regression analysis for the entire cohort (N=316) with multiple imputation to address missing data and logistic regression analysis for participants with complete data (N=169) are presented.
b
Absenteeism: Has the participant missed work time due to HD? Presenteeism: Does the participant experience impairment while working due to HD? Activity impairment: Is the participant’s activity impaired due to HD? Overall impairment: Is the participant’s overall work ability impaired due to HD?
c
Total Functional Capacity scale of the Unified Huntington’s Disease Rating Scale.
d
Physical component score of the 12-item Short-Form Health Survey (SF-12).
e
Mental component score of the SF-12.
No collinearity within the independent variables was identified based on the collinearity statistics (tolerance value above 0.2). The Hosmer-Lemeshow test was used to assess the goodness of fit, with a significant p value indicating poor model fit. Using this criterion, all regression models were assessed as having a good model fit.

Discussion

This cross-sectional study investigated significant factors associated with workplace impairment and disability in a cohort of employed individuals with HD with manifest motor symptoms. Almost eight in 10 participants reported having work-related activity impairment due to HD. Two in 10 reported missing work due to HD. Six in 10 participants reported both impairment while working due to HD and impairment in their overall work ability (work productivity loss) due to HD.
In terms of our hypotheses, the number of CAG repeats, motor symptoms, overall cognitive impairment, and physical impairments were not associated with higher odds of experiencing workplace impairment. However, we did find associations with mental health and functional status. Specifically, several significant predictors of absenteeism were identified. Individuals had 25% greater odds of missing work time (absenteeism) if they had a higher level of functional impairment. That is, participants with lower TFC scores were more likely to have missed work time (lower TFC scores reflect reduced functional capacity to work, handle finances, perform domestic chores and self-care tasks, and live independently). This was the finding of the analysis, even though most participants in this study fell within stages I and II of functional decline, indicating low levels of functional impairment (mean TFC score=11.5, SD=1.7, range=4–13). The strongest predictor of absenteeism was current alcohol use; current drinkers had almost three times greater odds of missing work, compared with nondrinkers (odds ratio=2.86, 95% CI=1.62, 5.03).
In terms of activity impairment, participants had 5% greater odds of experiencing impairment at work due to HD if they had a lower SF-12 MCS (indicating lower perceived mental health, including depression and anxiety symptoms and functional impairment as a consequence of psychological symptoms).
It is noteworthy that motor symptoms, the clinical hallmark of manifest HD, were not identified in this study as a predictor of workplace disability. This finding is consistent with a recent study that reported that motor symptoms did not predict unemployment in a sample of people with HD in The Netherlands (17). This might indicate that in people with HD, motor impairments may have less impact on occupational functioning than do functional capacity and mental well-being, both of which should be considered as a priority when evaluating workplace ability. Table 3 presents a comparison of data from the sample in our previous study of individuals with premanifest HD (18) and the sample in this study with manifest HD. Although the proportion of individuals reporting workplace disability was lower in the sample with premanifest HD, mental health problems were a significant factor in the same work disability outcome (activity impairment) in that sample. Unlike in the present study, alcohol use was not found to be a significant factor of any work disability outcomes in that asymptomatic cohort.
TABLE 3. Comparison of workplace disability in a sample of persons with premanifest Huntington’s disease (HD) and a sample with manifest HDa
 Premanifest (N=656)Manifest (N=316)
Disability area and variablebReported disability (%)Odds ratio95% CIReported disability (%)Odds ratioCI
Presenteeism12  60.1  
 CAG repeat length –1.181.06, 1.32   
 SF-12 MCSc 0.900.87, 0.93   
 SF-12 PCSd 0.940.90, 0.98   
 HADS-Ae 1.091.00, 1.20   
 UHDRS-TMSf 1.071.00, 1.14   
Activity impairment12.2  79.1  
 CAG repeat length 1.141.01, 1.29   
 SF-12 PCSd 0.940.90, 0.98   
 SF-12 MCSc 0.900.87, 0.93 0.950.90, 1.00
Overall work impairment12.7  60.8  
 CAG repeat length 1.181.06, 1.32   
 HADS-Ae 1.091.00, 1.20   
 UHDRS-TMSf 1.071.00, 1.14   
 SF-12 MCSc 0.900.87, 0.93   
 SF-12 PCSd 0.940.9, 0.98   
Absenteeism2.4  20.3  
 SF-12 MCSc 0.840.79, 0.89   
 Alcohol use    2.861.62, 5.03
 TFC scale scoreg    0.760.64, 0.91
a
Data for the sample with premanifest HD are from a previously published study (18).
b
Presenteeism: Does the participant experience impairment while working due to HD? Activity impairment: Is the participant’s activity impaired due to HD? Overall impairment: Is the participant’s overall work ability impaired due to HD? Absenteeism: Has the participant missed work time due to HD?
c
Mental component score of the 12-item Short-Form Health Survey (SF-12).
d
Physical component score of the SF-12.
e
Hospital Anxiety and Depression Scale anxiety subscale.
f
Total Motor Scale of the Unified Huntington’s Disease Rating Scale.
g
Total Functional Capacity scale of the Unified Huntington’s Disease Rating Scale.
There is well-established evidence that alcohol use, and particularly episodic heavy drinking, increases the risk of unemployment and, for working persons, absenteeism, and many studies have also suggested that alcohol consumption may have more effect on job productivity than on the number of workdays missed (34). However, despite much evidence of the negative impact of alcohol on work, the exact nature of the relationship between alcohol and workplace disability remains poorly understood. One hypothesis posits that this relationship is likely governed less by drinking or not drinking, but rather by the amount of alcohol consumed and even more by the way it is consumed (e.g., binge drinking versus moderate levels of alcohol consumption) (35). Additionally, it is also well established that alcohol can have a major impact on mental health, and alcohol use has been found to be especially associated with poor mental health functioning (36). Indeed, being at risk of or experiencing symptoms of younger onset dementia can cause significant stress. Drinking alcohol may be a coping strategy, as having a neurodegenerative illness, particularly one such as HD that is strongly genetically transmitted and typically affects multiple members of one family, can cause anxiety about the future, particularly as symptoms occur “out of time” in a “usual” life cycle, at a time when the individual often has significant family and financial responsibilities.
Overall, our results indicate a high level of workplace disability among persons with symptomatic HD and that mental health, functional status, and drinking alcohol are significant predictors of workplace disability. These results were significant in a group of clinically symptomatic individuals with minimal cognitive impairment and minimal functional limitations; no clinically relevant symptoms of depression, anxiety, or irritability; and an “average” level of physical and mental health. Thus, even in a group still working and reporting a high level of capacity, individuals were reporting significant workplace disability, with consequences for employees, employers, and the economy. Results highlight the importance of research into factors related to workplace disability in HD and its role in creating an evidence base for interventions.

Implications for Individuals, Clinicians, Employers, and Policy Makers

A recent systematic review noted that early identification of persons with dementia in the workplace, reasonable adjustments for people with dementia, and provision of information to raise awareness and facilitate informed choice were key factors in good employee management (37). Several key predictors of work disability outcomes identified in our study (current alcohol use and mental well-being) are modifiable and are potentially responsive to interventions. For example, there are many effective pharmacological and nonpharmacological treatments for mental health disorders, particularly for depression and anxiety. Based on our results, in order to minimize and delay workplace disability for persons with HD, health promotion should be a target for workplace health interventions, even if individuals report that they are functioning well. These health promotion interventions should strategically target mental health and well-being. Psychoeducation and teaching effective coping strategies could be incorporated into these interventions, which may potentially reduce alcohol use as a coping mechanism and may also positively affect functional capacity. These workplace interventions would be useful for all employees (regardless of diagnosis) and in all workplaces. Appropriate workplace support and modifications for persons with HD would engender inclusivity and diversity of employees, retain experienced workers, and keep persons with HD functioning within society for longer. Then, if and when they choose to leave the workforce, it can be done with dignity and choice.

Limitations and Future Research

We were limited in our choice of variables to those collected by the Enroll-HD study, and thus we were unable to explore other potential significant factors associated with workplace disability, such as job-related stress, job demands, and type of occupation. Exploring differences between occupations, such as between those with a greater or lesser degree of physical, cognitive, or emotional demands, may highlight important differences and identify occupation-specific predictors of workplace disability. In addition, it should be acknowledged that the Enroll-HD study relies on self-reported data for most outcomes. Because participants in this study had manifest HD, difficulties with capacity and insight may have affected the quality of the data collected. It is also well known that alcohol consumption is underreported in self-reports (38). Collection of collateral information from family members and employers may help to overcome this issue in future.
We also transformed some variables and combined some variable categories, leading to the loss of information. In addition, the size of the study cohort meant that it was not feasible to examine the interactions of variables associated with the outcomes. In future, we recommend longitudinal studies that examine time-dependent predictor variables to identify determinants of work disability outcomes in individuals with manifest HD and studies with larger samples so that interactions of variables can be investigated.
There is evidence that apathy is one of the most disabling behavioral symptoms for patients and caregivers, affecting up to 90% of individuals with HD (39). Greater levels of apathy have also been found to be related to less independence, increased motor impairment, and more clinician-rated behavioral problems (i.e., anger, irritability, and depression) (40). In addition, a recently published systematic review found that the most common significant factors associated with decreased functional capacity were depression and apathy (41). Given the prevalence of apathy among persons with HD reported in the literature and a recent study finding that apathy was an independent determinant of unemployment in HD mutation carriers (17), future research should include a measure of apathy in the methodology and analyses. This is particularly pertinent because our most significant predictors were related to absenteeism from work, which may be related to apathy manifesting as a reduction in the goal-directed behavior of attending work.
This study dichotomized participants into drinkers and nondrinkers because of small cell sizes, but it is also worth exploring the amount and type of alcohol consumption. There is a need to explore the extent of mental health problems in relation to alcohol consumption in order to guide interventions that decrease risk and improve psychological well-being and workplace ability of people with HD, particularly because substance abuse (including alcohol abuse) has been found to have a strong effect on the age at onset of motor symptoms in patients with HD in the Enroll-HD study (42). In addition, there are reports of positive aspects of leaving work, such as the sense of relief (43), which should be explored.
We used raw MMSE scores in our analysis, because we wished to directly compare findings in a premanifest and manifest cohort (Table 3), and previous studies have also found problems in the interpretation of transformed MMSE scores in specific populations (44). When we conducted an analysis after transforming MMSE scores to Z scores using established normative data (published 26 years ago) (45) to ascertain the potential influence of this approach to MMSE score interpretation on the study results, we observed two differences in the results of the multivariate regression following this analysis. Significant predictors of work productivity loss–overall work impairment included TFC score (odds ratio=−0.51, 95% CI=0.37, 0.96). In addition, where participants resided in the world (region) was a significant predictor of presenteeism (when workers come to work when they are unwell or attend work but work at levels that are less than optimal). The North and South American region had an odds ratio of 2.46 (95% CI=2.6, 77.8), and the European region had an odds ratio of 1.60 (95% CI=1.06, 23.3). All other results were the same. There is evidence to suggest that that the use of Z scores results in a loss of the meaningfulness of the raw score and standard deviation and may magnify certain effects and diminish others (46). Furthermore, we do not feel it is justified to transform MMSE raw scores into Z scores because age and education may influence not only MMSE scores but also other predictor variables employed in our study. Therefore, we elected to present the study results using raw MMSE scores. In addition, the participants represented a global cohort, with participants from Europe (64.2%), North and South America (30.7%), and Australasia (5.1%).
Although this study focused on worldwide predictors of workplace disability, it is known that the context of people’s lives determines their health. Future research should further investigate the social and economic determinants of employment and of health in HD, since the current literature is scarce in this area.

Conclusions

This study explored workplace disability in people with manifest HD in a sample of diverse, international participants. Almost eight in 10 participants reported having work-related activity impairment due to HD, highlighting the importance of research such as this into further understanding workplace disability in this cohort. Overall functioning, mental health, and alcohol use were established as important predictors of workplace disability in individuals with manifest HD. A better understanding of those who report workplace disability and of specific predictors or markers of occupational impairment is crucial to inform work accommodations and other strategies that may promote and facilitate continuing employment for those with manifest HD and inform the development of interventions and strategies to enhance engagement at work. Such findings may improve the international understanding of HD, and results may be useful in clinical evaluation, informing future policy, or developing strategies, which will help to delay unemployment and workplace disability and maintain individuals with HD in the workplace for as long as they wish and are able.

Acknowledgments

The authors thank the study participants and their families.

References

1.
Warr P: Work values: some demographic and cultural correlates. J Occup Organ Psychol 2008; 81:751–775
2.
Warr P, Jackson P: Factors influencing the psychological impact of prolonged unemployment and of re-employment. Psychol Med 1985; 15:795–807
3.
Roach P, Drummond N: “It’s nice to have something to do”: early-onset dementia and maintaining purposeful activity. J Psychiatr Ment Health Nurs 2014; 21:889–895
4.
McCulloch S, Robertson D, Kirkpatrick P: Sustaining people with dementia or mild cognitive impairment in employment: a systematic review of qualitative evidence. Br J Occup Ther 2016; 79:682–692
5.
Then FS, Luck T, Luppa M, et al: Systematic review of the effect of the psychosocial working environment on cognition and dementia. Occup Environ Med 2014; 71:358–365
6.
Luscombe G, Brodaty H, Freeth S: Younger people with dementia: diagnostic issues, effects on carers and use of services. Int J Geriatr Psychiatry 1998; 13:323–330
7.
DeBaggio T: Losing My Mind: An Intimate Look at Life With Alzheimer’s. New York, Free Press, 2002
8.
Beattie AM, Daker-White G, Gilliard J, et al: Younger people in dementia care: a review of service needs, service provision and models of good practice. Aging Ment Health 2002; 6:205–212
9.
Harris P, Keady J: Living with early onset dementia. Alzheimers Care Q 2004; 5:111–122
10.
Roach P, Keady J: Younger people with dementia: time for fair play. Br J Nurs 2008; 17:690
11.
Öhman A, Nygård L, Borell L: The vocational situation in cases of memory deficits or younger-onset dementia. Scand J Caring Sci 2001; 15:34–43
12.
MacDonald ME, Ambrose CM, Duyao MP, et al: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993; 72:971–983
13.
Paulsen JS, Langbehn DR, Stout JC, et al: Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 2008; 79:874–880
14.
van Duijn E, Kingma EM, Timman R, et al: Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington’s disease compared with mutation-negative first-degree relatives. J Clin Psychiatry 2008; 69:1804–1810
15.
Simpson JA, Lovecky D, Kogan J, et al: Survey of the Huntington’s disease patient and caregiver community reveals most impactful symptoms and treatment needs. J Huntingtons Dis 2016; 5:395–403
16.
Ritchie L: Dementia in the workplace. Maturitas 2017; 102:73–74
17.
Jacobs M, Hart EP, Roos RAC: Cognitive performance and apathy predict unemployment in Huntington’s disease mutation carriers. J Neuropsychiatry Clin Neurosci 2018; 30:188–193
18.
Goh AMY, You E, Perin S, et al: Predictors of workplace disability in a premanifest Huntington’s disease cohort. J Neuropsychiatry Clin Neurosci 2018; 30:115–121
19.
Group HS, Huntington Study Group: Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11:136–142
20.
Folstein MF, Folstein SE, McHugh PR: “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189–198
21.
Zigmond AS, Snaith RP: The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67:361–370
22.
Snaith RP, Taylor CM: Irritability: definition, assessment and associated factors. Br J Psychiatry 1985; 147:127–136
23.
Ware J Jr, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34:220–233
24.
Reilly MC, Zbrozek AS, Dukes EM: The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4:353–365
25.
Andréasson E, Svensson K, Berggren F: The validity of the Work Productivity and Activity Impairment Questionnaire for patients with asthma (WPAI-asthma): results from a web-based study. Value Health 2003; 6:780
26.
Boonen A, Boone C, Albert A, et al: Understanding limitations in at-work productivity in patients with active ankylosing spondylitis: the role of work-related contextual factors. J Rheumatol 2015; 42:93–100
27.
Delucchi KL, Bostrom A: Methods for analysis of skewed data distributions in psychiatric clinical studies: working with many zero values. Am J Psychiatry 2004; 161:1159–1168
28.
Pampaka M, Hutcheson G, Williams J: Handling missing data: analysis of a challenging data set using multiple imputation. Int J Res Method Educ 2016; 39:19–37
29.
Sterne JA, White IR, Carlin JB, et al: Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009; 338:b2393
30.
Chevret S, Seaman S, Resche-Rigon M: Multiple imputation: a mature approach to dealing with missing data. Intensive Care Med 2015; 41:348–350
31.
Hayati Rezvan P, Lee KJ, Simpson JA: The rise of multiple imputation: a review of the reporting and implementation of the method in medical research. BMC Med Res Methodol 2015; 15:30
32.
Hosmer DW, Lemeshow S, Sturdivant RX: Applied Logistic Regression, 3rd ed. New York, Wiley, 2013
33.
Tabrizi SJ, Scahill RI, Owen G, et al: Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 2013; 12:637–649
34.
Anderson P: Alcohol and the workplace, in Alcohol in the European Union: Consumption, Harm and Policy Approaches. Edited by Anderson P, Møller L, Galea G. Copenhagen, World Health Organisation Regional Office for Europe, 2012
35.
Bacharach SB, Bamberger P, Biron M: Alcohol consumption and workplace absenteeism: the moderating effect of social support. J Appl Psychol 2010; 95:334–348
36.
Salonsalmi A, Rahkonen O, Lahelma E, et al: The association between alcohol drinking and self-reported mental and physical functioning: a prospective cohort study among City of Helsinki employees. BMJ Open 2017; 7(e014368):e014368
37.
Thomson L, Stanyon M, Dening T, et al: Managing employees with dementia: a systematic review. Occup Med 2019; 69:89–98
38.
Stockwell T, Zhao J, Sherk A, et al: Underestimation of alcohol consumption in cohort studies and implications for alcohol’s contribution to the global burden of disease. Addiction 2018; 113:2245–2249
39.
Quaid KA, Eberly SW, Kayson-Rubin E, et al: Factors related to genetic testing in adults at risk for Huntington disease: the Prospective Huntington At-Risk Observational Study (PHAROS). Clin Genet 2017; 91:824–831
40.
Fritz NE, Boileau NR, Stout JC, et al: Relationships among apathy, health-related quality of life, and function in Huntington’s disease. J Neuropsychiatry Clin Neurosci 2018; 30:194–201
41.
Sellers J, Ridner SH, Claassen DO: A systematic review of neuropsychiatric symptoms and functional capacity in Huntington's disease. J Neuropsychiatry Clin Neurosci (Epub August 30, 2019)
42.
Schultz JL, Kamholz JA, Moser DJ, et al: Substance abuse may hasten motor onset of Huntington disease: evaluating the Enroll-HD database. Neurology 2017; 88:909–915
43.
McKillop J: Turning the corner when there’s someone there to help. J Dement Care 2005; 13:17–19
44.
Jervis LL, Fickenscher A, Beals J, et al: Predictors of performance on the MMSE and the DRS-2 among American Indian elders. J Neuropsychiatry Clin Neurosci 2010; 22:417–425
45.
Crum RM, Anthony JC, Bassett SS, et al: Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993; 269:2386–2391
46.
Beatty WW, Ryder KA, Gontkovsky ST, et al: Analyzing the subcortical dementia syndrome of Parkinson’s disease using the RBANS. Arch Clin Neuropsychol 2003; 18:509–520

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: 235 - 243
PubMed: 32102602

History

Received: 9 September 2019
Revision received: 2 January 2020
Accepted: 10 January 2020
Published online: 27 February 2020
Published in print: Summer 2020

Keywords

  1. Workplace Disability
  2. Huntington’s Disease
  3. Neurodegenerative Disease

Authors

Details

Anita M. Y. Goh, D.Psych. [email protected]
Department of Psychiatry, Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne (Goh, You, Perin, Lautenschlager, Chong, Ames, Chiu, Ellis); Neuropsychiatry Unit, Melbourne Neuropsychiatry Centre, Royal Melbourne Hospital, Melbourne (Goh, Loi); Department of Psychiatry, University of Melbourne, Melbourne (Goh, Lautenschlager, Clay, Ellis); NorthWestern Mental Health, Melbourne Health, Melbourne (Goh, Lautenschlager, Ellis); National Ageing Research Institute, Parkville, Australia (Goh); Department of Psychiatry, St. Vincent’s Hospital, University of Melbourne, Melbourne (Chong); School of Psychological Sciences, University of Melbourne, Melbourne (Ellis); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne (Ellis).
Emily You, Ph.D.
Department of Psychiatry, Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne (Goh, You, Perin, Lautenschlager, Chong, Ames, Chiu, Ellis); Neuropsychiatry Unit, Melbourne Neuropsychiatry Centre, Royal Melbourne Hospital, Melbourne (Goh, Loi); Department of Psychiatry, University of Melbourne, Melbourne (Goh, Lautenschlager, Clay, Ellis); NorthWestern Mental Health, Melbourne Health, Melbourne (Goh, Lautenschlager, Ellis); National Ageing Research Institute, Parkville, Australia (Goh); Department of Psychiatry, St. Vincent’s Hospital, University of Melbourne, Melbourne (Chong); School of Psychological Sciences, University of Melbourne, Melbourne (Ellis); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne (Ellis).
Stephanie Perin, M.Psych.
Department of Psychiatry, Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne (Goh, You, Perin, Lautenschlager, Chong, Ames, Chiu, Ellis); Neuropsychiatry Unit, Melbourne Neuropsychiatry Centre, Royal Melbourne Hospital, Melbourne (Goh, Loi); Department of Psychiatry, University of Melbourne, Melbourne (Goh, Lautenschlager, Clay, Ellis); NorthWestern Mental Health, Melbourne Health, Melbourne (Goh, Lautenschlager, Ellis); National Ageing Research Institute, Parkville, Australia (Goh); Department of Psychiatry, St. Vincent’s Hospital, University of Melbourne, Melbourne (Chong); School of Psychological Sciences, University of Melbourne, Melbourne (Ellis); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne (Ellis).
Nicola T. Lautenschlager, M.D.
Department of Psychiatry, Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne (Goh, You, Perin, Lautenschlager, Chong, Ames, Chiu, Ellis); Neuropsychiatry Unit, Melbourne Neuropsychiatry Centre, Royal Melbourne Hospital, Melbourne (Goh, Loi); Department of Psychiatry, University of Melbourne, Melbourne (Goh, Lautenschlager, Clay, Ellis); NorthWestern Mental Health, Melbourne Health, Melbourne (Goh, Lautenschlager, Ellis); National Ageing Research Institute, Parkville, Australia (Goh); Department of Psychiatry, St. Vincent’s Hospital, University of Melbourne, Melbourne (Chong); School of Psychological Sciences, University of Melbourne, Melbourne (Ellis); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne (Ellis).
Fiona J. Clay, Ph.D.
Department of Psychiatry, Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne (Goh, You, Perin, Lautenschlager, Chong, Ames, Chiu, Ellis); Neuropsychiatry Unit, Melbourne Neuropsychiatry Centre, Royal Melbourne Hospital, Melbourne (Goh, Loi); Department of Psychiatry, University of Melbourne, Melbourne (Goh, Lautenschlager, Clay, Ellis); NorthWestern Mental Health, Melbourne Health, Melbourne (Goh, Lautenschlager, Ellis); National Ageing Research Institute, Parkville, Australia (Goh); Department of Psychiatry, St. Vincent’s Hospital, University of Melbourne, Melbourne (Chong); School of Psychological Sciences, University of Melbourne, Melbourne (Ellis); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne (Ellis).
Samantha M. Loi, M.B.B.S., Ph.D.
Department of Psychiatry, Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne (Goh, You, Perin, Lautenschlager, Chong, Ames, Chiu, Ellis); Neuropsychiatry Unit, Melbourne Neuropsychiatry Centre, Royal Melbourne Hospital, Melbourne (Goh, Loi); Department of Psychiatry, University of Melbourne, Melbourne (Goh, Lautenschlager, Clay, Ellis); NorthWestern Mental Health, Melbourne Health, Melbourne (Goh, Lautenschlager, Ellis); National Ageing Research Institute, Parkville, Australia (Goh); Department of Psychiatry, St. Vincent’s Hospital, University of Melbourne, Melbourne (Chong); School of Psychological Sciences, University of Melbourne, Melbourne (Ellis); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne (Ellis).
Terence Chong, M.B.B.S., M.P.
Department of Psychiatry, Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne (Goh, You, Perin, Lautenschlager, Chong, Ames, Chiu, Ellis); Neuropsychiatry Unit, Melbourne Neuropsychiatry Centre, Royal Melbourne Hospital, Melbourne (Goh, Loi); Department of Psychiatry, University of Melbourne, Melbourne (Goh, Lautenschlager, Clay, Ellis); NorthWestern Mental Health, Melbourne Health, Melbourne (Goh, Lautenschlager, Ellis); National Ageing Research Institute, Parkville, Australia (Goh); Department of Psychiatry, St. Vincent’s Hospital, University of Melbourne, Melbourne (Chong); School of Psychological Sciences, University of Melbourne, Melbourne (Ellis); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne (Ellis).
David Ames, M.B.B.S., M.D.
Department of Psychiatry, Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne (Goh, You, Perin, Lautenschlager, Chong, Ames, Chiu, Ellis); Neuropsychiatry Unit, Melbourne Neuropsychiatry Centre, Royal Melbourne Hospital, Melbourne (Goh, Loi); Department of Psychiatry, University of Melbourne, Melbourne (Goh, Lautenschlager, Clay, Ellis); NorthWestern Mental Health, Melbourne Health, Melbourne (Goh, Lautenschlager, Ellis); National Ageing Research Institute, Parkville, Australia (Goh); Department of Psychiatry, St. Vincent’s Hospital, University of Melbourne, Melbourne (Chong); School of Psychological Sciences, University of Melbourne, Melbourne (Ellis); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne (Ellis).
Edmond Chiu, M.B.B.S., D.P.M.
Department of Psychiatry, Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne (Goh, You, Perin, Lautenschlager, Chong, Ames, Chiu, Ellis); Neuropsychiatry Unit, Melbourne Neuropsychiatry Centre, Royal Melbourne Hospital, Melbourne (Goh, Loi); Department of Psychiatry, University of Melbourne, Melbourne (Goh, Lautenschlager, Clay, Ellis); NorthWestern Mental Health, Melbourne Health, Melbourne (Goh, Lautenschlager, Ellis); National Ageing Research Institute, Parkville, Australia (Goh); Department of Psychiatry, St. Vincent’s Hospital, University of Melbourne, Melbourne (Chong); School of Psychological Sciences, University of Melbourne, Melbourne (Ellis); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne (Ellis).
Kathryn A. Ellis, Ph.D.
Department of Psychiatry, Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne (Goh, You, Perin, Lautenschlager, Chong, Ames, Chiu, Ellis); Neuropsychiatry Unit, Melbourne Neuropsychiatry Centre, Royal Melbourne Hospital, Melbourne (Goh, Loi); Department of Psychiatry, University of Melbourne, Melbourne (Goh, Lautenschlager, Clay, Ellis); NorthWestern Mental Health, Melbourne Health, Melbourne (Goh, Lautenschlager, Ellis); National Ageing Research Institute, Parkville, Australia (Goh); Department of Psychiatry, St. Vincent’s Hospital, University of Melbourne, Melbourne (Chong); School of Psychological Sciences, University of Melbourne, Melbourne (Ellis); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne (Ellis).

Notes

Send correspondence to Dr. Goh ([email protected]).

Competing Interests

The authors report no financial relationships with commercial interests.

Funding Information

CHDI Foundationhttp://dx.doi.org/10.13039/100005725: Enroll-HD
Enroll-HD, a longitudinal observational study for Huntington’s disease families intended to accelerate progress toward therapeutics, is sponsored by the Cure Huntington’s Disease Initiative Foundation, a nonprofit biomedical research organization exclusively dedicated to developing therapeutics for Huntington’s disease.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share